Results of recent multicenter studies on childhood non-Hodgkin lymphoma (NHL).
| . | . | . | . | Stages (St. Jude staging system) No. of patients/pEFS . | ||||
|---|---|---|---|---|---|---|---|---|
| Study . | Period . | No. patients (Age in y) . | pEFS at 3-5 y* . | I . | II . | III . | IV . | Comments . |
| * Total group. | ||||||||
| Abbreviations: pEFS Kaplan-Meier estimate of event-free survival; NG, not given; ADCOMP, L-asparaginase, daunorubicin, cyclophosphamide, vincristine, methotrexate, prednisone; L-asp, L-asparaginase; pCCR, probability of continuous complete remission; NE, not eligible; T-LBL, T-cell lymphoblastic lymphoma; B-ALL, B-cell acute lymphoblastic leukemia; HD-MTX, high-dose methotrexate | ||||||||
| Lymphoblastic Lymphoma | ||||||||
| CCG-5026 | 10/83-03/90 | 281 (0.5-19) | NG | — | I+II 28/84% | 219/70% | 34/46% | Randomized trial vs ADCOMP EFS 74% vs 64% Modified LSA2-L2 |
| POG 870421 | 05/87-;01/92 | 180 (1-21 ) | NG | NE | NE | NG | NG | Randomized trial: 20 weekly L-Asp vs no 4-y pCCR 78 vs 64% |
| NHL-BFM90-LBL5 | 04/90-03/95 | 105 (0.5-18) | 90% | 2/100% | 2/100 % | 82/90% | 19/95% | T-LBL only |
| NHL-BFM95-LBL23 | 04/95-03/01 | 198 (0-18) | 80% | I+II 22/95% | 123/79% | 53/77% | Omission of pre-emptive cranial irradiation | |
| SFOP-LMT 9622 | 02/97-12/03 | 83 (ng) | 87% | NG | NG | NG | NG | T-LBL only, BFM-backbone, early intensification day 8 |
| B-NHL | ||||||||
| POG Total9 | 10/86-11/91 | 133 (0-21) | NG | NE | NE | NE | 59/79% B-ALL 74/65% | |
| CCG-Hybrid10 | 12/91-12/93 | 42 (0-21) | 77% | NE | NE | 82% | 60% incl B-ALL | |
| SFOP/LMB 897 | 07/89-;06/96 | 561 (0-17) | 91% | 31/93% | 88/99% | 278/91% | 62/87%, B-ALL 102/87% | |
| NHL-BFM 908 | 04/90-03/95 | 413 (1-19) | 89% | 49/97% | 115/98% | 169/88% | 24/73%, B-ALL 56/74% | |
| NHL-BFM 9526 | 04/96-03/01 | 505 (0-18) | 89 % | 53/98% | 119/98% | 221/87% | 33/81% B-ALL 79/77% | Randomized trial HD-MTX intravenously over 24 h vs 4 h |
| FAB/LMB-96 | See Table 3 | |||||||
| Anaplastic Large Cell Lymphoma | ||||||||
| SFOP-HM89/9114 | 08/88-02/997 | 82 (1-17) | 66% | — | I/II 23/94% | — | III/IV 59/55% | |
| NHL-BFM-9012 | 04/90-03/95 | 89 (0.8-17) | 76% | 8/100% | 20/79% | 55/74% | 6/50% | |
| UKCCSG11 | 06/90-05/96 | 72 (0-17) | 59% | I/II 15/62% | III/IV 57/58% | |||
| AIEOP13 | 01/93-10/97 | 34 (4-15) | 65% | 0/− | 10/60% | 17/65% | 7/71% | |
| POG-8704-APO33 | 12/94-04/00 | 86 (0-21) | 72% | ne | ne | ng | ng | |
| . | . | . | . | Stages (St. Jude staging system) No. of patients/pEFS . | ||||
|---|---|---|---|---|---|---|---|---|
| Study . | Period . | No. patients (Age in y) . | pEFS at 3-5 y* . | I . | II . | III . | IV . | Comments . |
| * Total group. | ||||||||
| Abbreviations: pEFS Kaplan-Meier estimate of event-free survival; NG, not given; ADCOMP, L-asparaginase, daunorubicin, cyclophosphamide, vincristine, methotrexate, prednisone; L-asp, L-asparaginase; pCCR, probability of continuous complete remission; NE, not eligible; T-LBL, T-cell lymphoblastic lymphoma; B-ALL, B-cell acute lymphoblastic leukemia; HD-MTX, high-dose methotrexate | ||||||||
| Lymphoblastic Lymphoma | ||||||||
| CCG-5026 | 10/83-03/90 | 281 (0.5-19) | NG | — | I+II 28/84% | 219/70% | 34/46% | Randomized trial vs ADCOMP EFS 74% vs 64% Modified LSA2-L2 |
| POG 870421 | 05/87-;01/92 | 180 (1-21 ) | NG | NE | NE | NG | NG | Randomized trial: 20 weekly L-Asp vs no 4-y pCCR 78 vs 64% |
| NHL-BFM90-LBL5 | 04/90-03/95 | 105 (0.5-18) | 90% | 2/100% | 2/100 % | 82/90% | 19/95% | T-LBL only |
| NHL-BFM95-LBL23 | 04/95-03/01 | 198 (0-18) | 80% | I+II 22/95% | 123/79% | 53/77% | Omission of pre-emptive cranial irradiation | |
| SFOP-LMT 9622 | 02/97-12/03 | 83 (ng) | 87% | NG | NG | NG | NG | T-LBL only, BFM-backbone, early intensification day 8 |
| B-NHL | ||||||||
| POG Total9 | 10/86-11/91 | 133 (0-21) | NG | NE | NE | NE | 59/79% B-ALL 74/65% | |
| CCG-Hybrid10 | 12/91-12/93 | 42 (0-21) | 77% | NE | NE | 82% | 60% incl B-ALL | |
| SFOP/LMB 897 | 07/89-;06/96 | 561 (0-17) | 91% | 31/93% | 88/99% | 278/91% | 62/87%, B-ALL 102/87% | |
| NHL-BFM 908 | 04/90-03/95 | 413 (1-19) | 89% | 49/97% | 115/98% | 169/88% | 24/73%, B-ALL 56/74% | |
| NHL-BFM 9526 | 04/96-03/01 | 505 (0-18) | 89 % | 53/98% | 119/98% | 221/87% | 33/81% B-ALL 79/77% | Randomized trial HD-MTX intravenously over 24 h vs 4 h |
| FAB/LMB-96 | See Table 3 | |||||||
| Anaplastic Large Cell Lymphoma | ||||||||
| SFOP-HM89/9114 | 08/88-02/997 | 82 (1-17) | 66% | — | I/II 23/94% | — | III/IV 59/55% | |
| NHL-BFM-9012 | 04/90-03/95 | 89 (0.8-17) | 76% | 8/100% | 20/79% | 55/74% | 6/50% | |
| UKCCSG11 | 06/90-05/96 | 72 (0-17) | 59% | I/II 15/62% | III/IV 57/58% | |||
| AIEOP13 | 01/93-10/97 | 34 (4-15) | 65% | 0/− | 10/60% | 17/65% | 7/71% | |
| POG-8704-APO33 | 12/94-04/00 | 86 (0-21) | 72% | ne | ne | ng | ng | |